All You Need to Know About ResMed (RMD) Rating Upgrade to Buy

ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), driven by an upward trend in its earnings estimates, including a 0.2% increase in the Zacks Consensus Estimate for fiscal year 2025 EPS to $9.48. This upgrade, reflecting an improving earnings outlook, positions RMD in the top 20% of Zacks-covered stocks, suggesting potential for near-term buying pressure and stock price appreciation given the system's correlation between estimate revisions and stock performance.

Analysis

ResMed (RMD) has received a rating upgrade to a Zacks Rank #2 (Buy), a designation driven exclusively by positive revisions in analyst earnings estimates. This upgrade places the company in the top 20% of stocks covered by the Zacks system, which historically correlates with near-term stock price appreciation due to increased institutional interest. Specifically, the Zacks Consensus Estimate for the fiscal year ending June 2025 has risen by 0.2% over the last three months. However, it is critical to note that the resulting consensus earnings per share (EPS) forecast of $9.48 represents zero anticipated year-over-year growth. Therefore, while the marginal upward revision in estimates signals improving analyst sentiment, the underlying projection points to a flat earnings trajectory for the upcoming fiscal year, suggesting a potential stabilization rather than a robust acceleration in business fundamentals.

Key Decisions for Investors

• The Zacks Rank #2 upgrade provides a tactical positive signal for near-term momentum, potentially attracting investors who trade on quantitative rating changes and analyst sentiment shifts.
• Long-term investors should exercise caution, as the fiscal 2025 EPS forecast of $9.48 implies a flat year-over-year growth profile, which may cap significant stock price upside if fundamentals do not improve.
• It is prudent to monitor subsequent earnings estimate revisions to see if the positive trend accelerates, as the current 0.2% upward adjustment is modest and may not be sufficient to signal a sustained business recovery.